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Abstract
Background: The pathophysiology of schizophrenia (SCZ) remains unclear, and its treatment is far from ideal.
We have previously reported that yokukansan (YKS), which is a traditional Japanese medicine, is effective as an
adjunctive therapy for SCZ. However, the mechanisms underlying the action of YKS have not yet been completely
elucidated. A recent meta-analysis study has shown that adjuvant anti-inflammatory drugs are effective for SCZ
treatment, and it has been proposed that some of the cognitive deficits associated with inflammation may in part
be related to inflammation-induced reductions in adult hippocampal neurogenesis. Although certain ingredients of
YKS have potent anti-inflammatory activity, no study has determined if YKS has anti-inflammatory properties.
Methods: Using the Gunn rat, which has been reported as a possible animal model of SCZ, we investigated
whether YKS affects cognitive dysfunction in an object-location test and the suppression of microglial activation
and neurogenesis in the hippocampus.
Results: We found that YKS ameliorated spatial working memory in the Gunn rats. Furthermore, YKS inhibited
microglial activation and promoted neurogenesis in the hippocampal dentate gyrus of these rats. These results
suggest that the ameliorative effects of YKS on cognitive deficits may be mediated in part by the suppression of
the inflammatory activation of microglia.
Conclusions: These findings shed light on the possible mechanism underlying the efficacy of YKS in treating SCZ.
Keywords: Anti-inflammatory action, Cognitive function, Microglia, Neurogenesis, Schizophrenia (231/350),
Unconjugated bilirubin, Yokukansan
Background
Schizophrenia (SCZ) is one of the most intriguing psy-
chological disorders; it has a huge adverse impact on
quality of life and requires high expenditure for treat-
ment [1]. Although the pathophysiology of SCZ is still
far from being completely elucidated, researchers have
indicated hippocampal neurogenesis as a key target for
the pathogenesis and treatment of this disease [2]. The
hippocampus, which plays an important role in learning
and memory processes and mood regulation, has been
the subject of numerous studies addressing the cause of
SCZ [3]. There are ample preclinical evidences suggest-
ing that SCZ is related to decreased hippocampal neuro-
genesis [2]. Moreover, neuroinflammation associated
with activated microglia is negatively correlated with the
survival rates of hippocampal neurons [4]. A positron
emission tomography-based study has shown activated
microglial cells in the hippocampus of patients with SCZ
during the psychotic state [5]. Moreover, previous stud-
ies have suggested that adjuvant anti-inflammatory drugs
are effective for treating SCZ [6].
From the standpoint of the heterogeneity of SCZ, pre-
vious studies have indicated a close association between
unconjugated bilirubin (UCB) and SCZ [7,8]. UCB acti-
vates microglia and induces the release of proinflamma-
tory cytokines from microglia [9]. On the basis of these
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findings, we suggested that elevated levels of UCB play
an important role in SCZ etiology, and that the Gunn
rat, which exhibits a high concentration of UCB, is use-
ful as an animal model of SCZ [10-12]. Furthermore,
our previous studies have shown that Gunn rats have
cognitive deficits [10] and contain activated microglia in
the hippocampus [11].
We recently reported that yokukansan (YKS), which is
a traditional Japanese medicine (termed ‘kampo medi-
cine’ in Japan), is effective as an adjunctive therapy for
treatment-resistant SCZ [13]. To date, basic studies have
suggested that both the glutamate and serotonin signal-
ing pathways are involved in the antipsychotic action of
YKS [14,15]. In addition, several in vitro studies have
reported the neuroprotective effects of YKS [16,17]
and some human studies have demonstrated the effect-
iveness of YKS in regulating emotion [18,19], implying
that YKS promotes hippocampal neurogenesis. Tanaka
and Mizoguchi demonstrated that YKS has neurogenic
effects in aged rats [20]. Furthermore, facilitated
hippocampal neurogenesis may be associated with the
anti-inflammatory action of YKS, as several ingredients
of YKS possess potential anti-inflammatory properties
(Table 1).
Recently, it was suggested that cognitive dysfunction
in SCZ shows high prevalence, is relatively stable over
time, and is independent of psychotic symptoms [21].
Moreover, cognitive dysfunction is present in healthy
relatives of SCZ patients, and it has been suggested as a
biomarker of SCZ. As a consequence, disturbances
in critical cognitive process, such as spatial working
memory, are regarded as a core feature of SCZ [22].
Moreover, object-location test (OLT) has been used to
test cognitive dysfunction, especially spatial working
memory [23].
In this study, we hypothesized that YKS is effective in
treating SCZ by promoting hippocampal neurogenesis
and, in part, via its anti-inflammatory actions. We inves-
tigated whether YKS affects cognitive functions involved
in performing the OLT. To gain further insight into the
neurobiological effects of YKS, microglial activation and




Seven-week-old male homozygous (j/j) Gunn rats and
male Wistar rats (Japan SLC, Inc., Shizuoka, Japan) were
used in this study. The rats were housed in plastic cages
(39 × 27 × 18 cm) under standard conditions (tempera-
ture, 23 ± 2°C; humidity, 55 ±5 %; 12 h light/dark cycle
[light phase from 07:00 to 19:00 h]) and were given free
access to food and water. One week before the experi-
ment, the rats underwent a handling procedure once
daily to reduce stress during the experiment. All proce-
dures were performed with the approval of the Shimane
University Animal Ethics Committee, under the guide-
lines of the National Health and Medical Research
Council of Japan.
Drugs
YKS (Tsumura & Co., Tokyo, Japan) is composed of
seven dried medical herbs (Table 1). Each plant material
was authenticated by identifying the external morph-
ology and marker compounds of plant specimens ac-
cording to the methods of the Japanese Pharmacopoeia
and the company’s standard. The seven medical herbs
were mixed and extracted with purified water at 95°C
for 1 h, and the extraction solution was filtered and con-
centrated under reduced pressure; spray-drying was used
to produce dried extract powder and the extract yield
was approximately 15.9%. The dosage (1 g/kg) of YKS
used in this study was decided upon based on the results
of previous studies demonstrating that YKS ameliorated
SCZ-like symptoms [24], cognitive deficits [25], and ag-
gressive behavior [14] in rats and mice. This dosage is
approximately 20 times of the clinical dose in humans.
We previously demonstrated that YKS was effective in
patients with SCZ (13) and Behavioral and psychological
symptoms of dementia [26]. Although the difference be-
tween an effective dosage in animals and humans is un-
certain, these dosages are thought to be equivalent to
ameliorate psychological symptoms. Recently, several
alkaloid and triterpenoid components were detected in
the plasma and brain of rats orally administered YKS
[27-29]. However, pharmacokinetic studies in humans
have not yet been performed. Such studies are necessary











4.0 Pachymic acid [37]
Cnidium
rhizome
3.0 Senkyunolide A [30]
Z-Ligustilide [30]
Ferulic acid [36]




3.0 Ferulic acid [36]
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to examine the pharmacokinetics of YKS components in
humans and be able to clarify the detailed mechanisms
and the difference of effective dosages.
Experimental design
The rats were divided into four groups: Wistar-control
(WC) group, Wistar-YKS (WY) group, Gunn-control
(GC) group, and Gunn-YKS (GY) group. The rats in the
control groups (WC and GC) were given drug-free water
ad libitum for 6 weeks, whereas those in the YKS-
treated groups (WY and GY) were given water contain-
ing 0.6% YKS (corresponding to a dosage of 1 g/kg of
body weight) for the same period. Each group of animals
received intraperitoneal injections of 50 mg/kg bromo-
deoxyuridine (BrdU; Sigma-Aldrich, St. Louis, MO,
USA), four times a day (with an interval of 2 h) during
the last two weeks of drug dosing. The OLT for each
animal was performed for 1 h after the final administra-
tion of test substance on the sixth week. After the behav-
ioral test was finished, the rats were anesthetized deeply
via intraperitoneal injection of 80 mg/kg sodium pentobar-
bital and perfused transcardially with 500 mL of physio-
logical saline, followed by 500 mL of 4% paraformaldehyde
in 0.1 M phosphate buffer (PB; pH 7.3). After perfusion,
the brain was removed quickly and post-fixed in the same
fixing solution at room temperature for 4 h. The brain was
immersed overnight in 20% sucrose solution at 4°C and
used later for immunohistochemical analysis.
OLT
The OLT behavioral test was performed according to
the previously described procedure [23]. The experimen-
tal apparatus used in this study was an open-field box
(42 × 42 × 42 cm) made of gray polyvinyl chloride. Iden-
tical plastic columns (26 cm in height × 7 cm in diam-
eter) were used as objects. During habituation, rats were
allowed to explore the apparatus without objects freely
for 1 h on the day before the acquisition trial. During
the acquisition trial, each rat was allowed 5 min to ex-
plore two identical objects that were placed in the cor-
ners of the experimental apparatus. A test trial was
conducted 1 h after the acquisition trial. In the test trial,
one of the two objects used in the acquisition trial was
placed at a new location. The rat was again placed in the
open field for 5 min, and the extent of exploration was
assessed by measuring the total time spent in explora-
tory behavior, such as sniffing, licking, or touching the
object while facing it. During both the acquisition and
test trials, the rat’s behavior was observed using a cam-
era located over the open field, and recorded on video-
tape. All behaviors were analyzed by three blind raters.
The location index (LI), which is the percentage of time
spent exploring the object placed in the new location
during a test trial, was calculated as follows: LI (%) =
(time spent exploring the object in a new location)/(time
spent exploring the object in a new location + time spent
exploring the object in the familiar location) × 100.
Immunohistochemistry
The brains were immersed in 20% sucrose solution sec-
tioned at a thickness of 40 μm at the frontal plane using a
freezing microtome. The sections were divided into four
series to visualize the expression of the ionized calcium-
binding adapter molecule I (Iba1, a marker of microglia/
macrophages [30]), CD11b (CD11b expression is up-
regulated in activated microglia [31]), Iba1/CD11b, and
BrdU/NeuN. The labeling procedures for visualization of
immunoperoxidase and double-immunofluorescence, and
the morphometric analytical procedure were as follows.
Immunoperoxidase labeling
Iba1 or CD11b expression was visualized as described
previously [11]. Sections treated with either rabbit anti-
Iba1 (1:4000, Wako, Osaka, Japan) or mouse anti-CD11b
(1:500, Serotec, Oxford, UK) antibodies were incubated
overnight at room temperature on a rotatory shaker.
The sections were then treated using a standard ABC
Kit procedure (Vector Labs, CA, USA). Subsequently,
the sections were developed by incubating in PBS con-
taining 10 mg diaminobenzidine (DAB) and 5 μL of 30%
hydrogen peroxide for 10 min.
Double-immunofluorescence labeling
The sections were incubated with the primary antibodies
rabbit anti-Iba1 (1:4,000) and mouse anti-CD11b (1:500).
Subsequently, the sections were incubated in PBS con-
taining Cy3-conjugated anti-Iba1 rabbit IgG (1:1,000,
Jackson, PA, USA) and Alexa488-conjugated anti-CD11b
mouse IgG (1:1,000, Invitrogen, Oregon, USA) for 1 h at
room temperature. For detecting BrdU incorporation,
brain sections were incubated in 50% formamide and
2× standard sodium citrate for 2 h at 65°C, followed by
incubation in 2 N HCl for 30 min at 37°C, rinsing in
100 mM boric acid (pH 8.5) for 10 min at 25°C, and
washing with 0.25% Triton X-100 in Tris-buffered saline
(pH 7.4). The sections were incubated with the primary
antibodies (rat anti-BrdU IgG [1:10, Serotec] and mouse
anti-NeuN [1:200, Millipore Inc., CA, USA]), followed
by incubation with Cy3-conjugated anti-BrdU rat IgG
(1:500, Abcam, Tokyo, Japan) and Alexa488-conjugated
anti-NeuN mouse IgG (1:1,000, Invitrogen). All sections
were visualized using a confocal laser-scanning micro-
scope (Olympus FV-300, Tokyo, Japan) and the Fluo-
View software (Olympus).
Morphometric analysis
To estimate the number of Iba1-expressing microglial
cells, images were captured from different regions of the
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hippocampal dentate gyrus (DG): the hilus, subgranular
zone (SGZ), and granular layer (GL). A 70 × 70-μm box
was then placed randomly within the region of interest
(from interaural 5.88 mm, Bregma −3.12 mm to inter-
aural 4.20 mm, Bregma −4.80 mm) on the basis of a
stereotaxic atlas of the rat brain [32]. For each analysis,
there were about 650 boxes per region in each sample.
The images were analyzed using the Stereo Investigator
software Ver. 7.0 (MicroBrightField Inc., Williston, VT,
USA). The number of Iba1-labeled cells in the region of
interest was calculated automatically by the software.
The immunoreactive area was measured using a com-
puter-assisted image analysis program (ImageJ 1.46r;
National Institutes of Health, Bethesda, MD, USA).
Sections containing CD11b-labeled cells were examined
under a light microscope (Nikon, ECLIPSE E800). Images
(n = 20 examined at each time point) were captured from
the region of interest, and the areas were analyzed using
the Image J 1.46r software. The BrdU+/NeuN+ double-
labeled cells were counted throughout the DG (the same
region as described above) by three blind raters.
Statistical analyses
Results were analyzed by one-way analysis of variance
(ANOVA) and post hoc Bonferroni test to determine
differences among groups. Values are expressed as the
mean ± SEM. Analyses were performed using the Statis-
tical Package for the Social Sciences software. In the
analyses, P values <0.05 were considered statistically
significant.
Results
Effect of YKS on the performance of Gunn rats in the OLT
Previous reports have indicated that YKS treatment
stimulates neurogenesis related to cognitive function
[20]. To clarify the hypothesis, we examined the effect of
YKS on cognitive deficits in Gunn rats using the OLT,
which is a cognitive test for spatial memory based on
the spontaneous tendency of rodents to explore novel
stimuli [23]. In the present study, this behavioral test
was performed 6 weeks after starting YKS administra-
tion, because the critical period for enhanced synaptic
plasticity in newly generated neurons is 4–6 weeks [33].
During the acquisition test, no significant differences
were observed among the four groups (data not shown).
On the other hand, in the test trial (Figure 1), the LI was
70.38 ± 4.85% in the WC group, 68.60 ± 3.42% in
the WY group, 49.68 ± 4.94% in the GC group, and
69.28 ± 3.73% in the GY group. In other words, the
effect of YKS on the LI in Wistar rats was not observed
at all, but the LI in Gunn rats (GC) was significantly
lower (P = 0.014) than that in Wistar rats (WC), suggest-
ing that cognitive function was disturbed in Gunn rats.
The lowered LI, i.e., the disturbed cognitive function in
Gunn rats, was ameliorated to control level (WC) by
treatment of YKS (P = 0.021).
Effect of YKS on activated microglia in the DG of Gunn
rats
Confocal microscopy of Iba1-labeled microglial cells
Microglial cells were located in the SGZ of the GC
and GY rats (Figure 2A,B). There was no significant
difference in the number of microglial cells in the DG
among the four groups (Figure 2C): 25,623.50 ± 2067.45
in the WC group, 26,248.83 ± 2047.80 in the WY group,
24,508.83 ± 1099.36 in the GC group, and 24,771.50 ±
1314.260 in the GY group.
CD11b immunoreactivity in Iba1-labeled microglial cells
Next, we evaluated the effect of YKS on microglial acti-
vation in the DG. CD11b expression in Iba1-labeled
microglial cells in the DG was compared between the
GY and GC groups (Figure 3A–H). Our results showed
that, compared with the microglial cells in the GC
group (Figure 3C,D), microglial cells in the GY group
(Figure 3G,H) exhibited lower levels of CD11b immuno-
reactivity. Furthermore, we quantified CD11b immuno-
reactivity in the DG for all groups. The mean percentage
of black pixels for CD11b immunoreactivity in the DG
was 19.05% (% area) in the WC group, 17.33% in the
WY group, 26.25% in the GC group, and 21.29% in the
GY group. Statistical analysis showed that the CD11b
immunoreactivity in the DG of the GY group was 18.9%
lesser than that in the GC group (P = 0.034). The CD11b
immunoreactivity in the DG was significantly higher in
the GC group than in the WC group (P = 0.02). We ob-
served no significant differences between the WC, WY,
and GY groups (Figure 3I).
Effect of YKS on neurogenesis in the DG of Gunn rats
To determine the survival of newly born neurons in the
DG, the number of NeuN + cells among BrdU-labeled
cells (BrdU+/NeuN + cells) was examined immunohisto-
chemically 4 weeks after the final injection of BrdU
(Figure 4A–D). The number of BrdU+/NeuN + neurons
was 180.13 ± 24.11 in the WC group, 248.75 ± 17.38 in
the WY group, 208.50 ± 26.37 in the GC group, and
309.75 ± 15.62 in the GY group. YKS (GY group) signifi-
cantly ameliorated the decrease in the number of cells
observed in the GC group (P = 0.034). There were no
significant differences between the WC, WY, and GC
groups (Figure 4E).
Discussion
The purpose of the present study was to determine
whether chronic YKS treatment ameliorates the cogni-
tive deficits associated with SCZ in Gunn rats. Further-
more, we investigated whether YKS suppresses microglial
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activation and promotes neurogenesis in the DG of Gunn
rats. This study yielded three major findings, which are
discussed below.
First, YKS ameliorated the cognitive dysfunction of
Gunn rats. This finding suggests that YKS enhances the
integration of newly born cells into the existing neural
network in the DG. In our previous study, a cognitive
deficit was observed in Gunn rats during the prepulse
inhibition test [10]. The perirhinal cortex [34] and
hippocampus [35] are involved in object-recognition
and object-location memory, respectively. Moreover,
performance in the OLT relies on an intact DG, and not
on other subregions [36]. Accordingly, the OLT was
used in the present study to determine if YKS restores
the function of the hippocampus through neurogenesis.
Our result showed that amelioration of cognitive func-
tion in the OLT by YKS is consistent with the findings
of a previous study that used the prepulse inhibition test
Figure 1 Effect of YKS on the performance of Gunn rats in the OLT. YKS ameliorated the cognitive dysfunction observed in Gunn rats.
Data are presented as the mean ± S.E.M. (n = 4, respectively). *P <0.05, ANOVA followed by Bonferroni post hoc test.
Figure 2 Effect of YKS on the number of activated microglia in the DG of Gunn rats. Microglial cells located in the SGZ of control Gunn
rats (GC) (A) and YKS-treated Gunn rats (GY) (B). There were no significant differences in the number of microglial cells in the DG among all
groups (C). SGZ: subgranular zone, GL: granular layer. Scale bar, 100 μm. Data are presented as the mean ± SEM (n = 4).
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[24]. To the best of our knowledge, the effects of YKS
on cognitive function in the animal models of SCZ have
only been demonstrated in the present study (using
Gunn rats) and in a study, performed by Makinodan,
using poli (I:C) [24]. However, there were no significant
differences between the WC, WY, and GC groups
(Figure 4E). These results suggested that the behavioral
abnormalities of Gunn rats do not relate to the dysfunc-
tion in neurogenesis in the hippocampus and that YKS
ameliorated the cognitive deficit in Gunn rats through a
mechanism other than the increase of neurogenesis in
the hippocampus.
Second, YKS suppressed microglial activation in the
DG of Gunn rats. We presume that this result reflects
the potent anti-inflammatory activity of YKS [37-47]. A
highly characteristic feature of microglia activation is
the remarkable capacity of cell populations to expand,
especially in response to acute injury. This expansion is
usually transient and has been considered to be predom-
inantly due to proliferation of activated microglia cells
[48,49]. Our results showed no significant difference
between the numbers of microglia cells in Gunn rats
compared to the controls. However, we found a signifi-
cant difference in microglial activation, which was
Figure 3 Effect of YKS on the expression of activated microglia in the DG of Gunn rats. YKS suppressed microglial activation in the DG of
Gunn rats. A confocal Z-stack image depicting Iba-1 (red), CD11b (green), and a merged image (yellow) of cells in the DG of control Gunn rats
(A–D) and YKS-treated Gunn rats (E–H). Microglial cells in YKS-treated Gunn rats exhibited a low level of CD11b immunoreactivity (IR) compared
with those in control Gunn rats (C, G). Scale bar, 100 μm (A, E), 50 μm (B–D, F–H). (I) Mean percentage of black pixels indicating CD11b immu-
noreactivity in the DG. Data are presented as the mean ± SEM (n = 4, respectively). *P <0.05, ANOVA followed by Bonferroni post hoc test.
Figure 4 Effect of YKS on neurogenesis in the DG of Gunn rats. YKS increased the survival of newly born neurons in the DG. (A) Survival of
newly generated cells in the DG. (B–D) Representative high-magnification photomicrograph of confocal images of the area depicted by the white
square in A confirmed the colocalization of both BrdU and NeuN staining. (D) Arrows indicate double-positive cells (yellow). (E) YKS increased
the number of BrdU+/NeuN + cells in the DG of Gunn rats. Scale bar, 100 μm (A). Data are presented as the mean ± SEM (n = 4, respectively).
*P <0.05, ANOVA followed by Bonferroni post hoc test.
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suppressed by the administration of YKS. These results
suggest that microglial cells in adult Gunn rats showed a
feature of activated microglial cells without expansion of
the cell population, indicating chronic microglial activa-
tion. A recent meta-analysis study has suggested that
anti-inflammatory drugs, such as COX-2 inhibitors, as-
pirin, and minocycline, are effective in SCZ treatment
[6,48,49]. Kohman et al. reported that the minocycline-
induced spatial learning improvement in aged mice
might be related to inhibition of microglial cells [4].
They observed a significant reduction in the average the
size and total number of Iba-1-positive cells in the mo-
lecular layer of the DG following minocycline treatment.
However, long-term use of these drugs increases the risk
of complications, i.e., COX-2 inhibitors [50], aspirin
[51], and minocycline [52] induce adverse cardiovascular
events, gastric ulcers and gastrointestinal bleeding, and
emergence of drug-resistant strains of bacteria, respect-
ively. Therefore, it is difficult to use these drugs in clin-
ical treatment for a prolonged period. YKS has exhibited
high safety and tolerability in several clinical studies
[13,18,19]. Nevertheless, although we demonstrated that
YKS suppressed the microglial activation in this study,
we did not evaluate its effect on inflammatory markers,
such as proinflammatory cytokines and chemokines.
Therefore, further studies are needed to determine if
YKS has anti-inflammatory potency.
Third, YKS promoted the survival of new neurons in
the DG of Gunn rats. We suppose that this finding was,
in part, due to the suppression of activated microglia in
the DG by YKS. Several studies have suggested that the
inflammation associated with activated microglia is det-
rimental to the survival of new hippocampal neurons
[53]. In addition, inflammation affects functional integra-
tion of newborn neurons [54]. A study using postmor-
tem brain material suggested that neurogenesis is more
related to the pathophysiology of SCZ than to that of
depression [55]. Furthermore, several neuroimaging
studies have shown that hippocampal volume and activ-
ity are significantly decreased in SCZ [56]. In addition,
disrupted-in-schizophrenia 1, which is one of the most
widely investigated SCZ susceptibility genes, regulates
the integration of newly generated neurons in the adult
brain [57]. Therefore, we evaluated whether YKS affects
hippocampal neurogenesis in the DG of Gunn rats.
The mechanisms through which inflammation reduces
hippocampal neurogenesis are still not fully understood,
but evidence indicates that activation of microglia and
the subsequent release of inflammatory molecules cre-
ates an environment that does not support survival of
new cells. Evidence suggests that classic proinflamma-
tory cytokines, IL-1b, IL-6, and TNF-α contribute to the
inflammation-related decrease in neurogenesis [48,49].
Therefore, studying the effects of YKS on the production
of classic proinflammatory cytokines, IL-1b, IL-6, and
TNF-α is thoroughly important.
Finally, in this study, we predicted that hippocampal
neurogenesis would be significantly decreased in Gunn
rats compared to Wistar rats. Despite the fact that the
in vivo study of the ameliorative effects of YKS on cogni-
tive dysfunction is not the first to be performed, and
although the evidence of cognitive recovery, microglial
activation suppression, and promotion of neurogenesis
by YKS shown herein are very important, we could not
conclude their relation through the experiments per-
formed in this manuscript. However, surprisingly, our
results showed no significant differences in the number
of surviving newly generated neurons between Gunn
and Wistar rats. We speculate that this finding might
represent a phenomenon of compensation by neuronal
homeostasis since Gunn rats have high concentrations
of UCB, which is detrimental to the CNS of neonates
[58]. Furthermore, we presume that the total number of
hippocampal neurons in Gunn rats decreases more than
in Wistar rats.
Limitations
First, we had investigated about the antipsychotic effects
of sole YKS, unfortunately, we had no data comparing
YKS with other antipsychotics; therefore, we could not
mention the differences between effects of YKS and
other antipsychotics. Second, in Figure 4 of the effect of
YKS on neurogenesis in the DG, it seems to increase
even if in DG of Wistar though it was not significant.
We should demonstrate weather there was any tendency
about this change, and the possible reasons why it
caused especially in Gunn rats. However, it is very diffi-
cult to explain these results. However, these points are
very important subjects, so that we are investigating
about these subjects.
Conclusions
To the best of our knowledge, this is the first in vivo
study showing that YKS ameliorates cognitive dysfunc-
tion, suppresses microglial activation in the DG, and
promotes hippocampal neurogenesis. The effects of YKS
in SCZ may occur partly via the suppression of the in-
flammatory activation of microglia. Our results suggest a
possible mechanism to explain the efficacy of YKS in
SCZ and contribute to a better understanding of the
pathophysiology of this disease.
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